article Open AccessTop 1% cited

Intravitreal Aflibercept for Diabetic Macular Edema

Ophthalmology · 2014 · Vol. 121(11) · pp. 2247–2254

Jean‐François Korobelnik(Université de Bordeaux)V. Diana(University of Nebraska Medical Center)Ursula Schmidt‐Erfurth(Medical University of Vienna)David S. Boyer(Retina Vitreous Associates Medical Group)Frank G. Holz(University of Bonn)Jeffrey S. Heier(Ophthalmic Consultants of Boston)Edoardo Midena(University of Padua)Peter K. Kaiser(Cleveland Eye Clinic)Hiroko Terasaki(Nagoya University Hospital)Dennis M. Marcus(Southeast Retina Center)Quan Dong Nguyen(University of Nebraska Medical Center)Glenn J. Jaffe(Duke University)Jason S. Slakter(Vitreous Retina Macula Consultants of New York)Christian Simader(Medical University of Vienna)Yuhwen Soo(Regeneron (United States))Thomas Schmelter(Bayer (Germany))George D. Yancopoulos(Regeneron (United States))Neil Stahl(Regeneron (United States))Robert Vitti(Regeneron (United States))Alyson J. Berliner(Regeneron (United States))Oliver Zeitz(Bayer (Germany))Carola Metzig(Bayer (Germany))David M. Brown✉(Retina Consultants of Houston)

View via DOI Full-text PDF

Retinal Diseases and Treatments Retinal Imaging and Analysis Glaucoma and retinal disordersMedicineAfliberceptDiabetic retinopathyOphthalmologyVisual acuityMacular edemaDiabetic macular edemaRetinalLaser coagulationClinical endpoint

MeSH terms

AgedDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyDouble-Blind MethodFemaleHumansMacular EdemaMaleMiddle AgedRecombinant Fusion ProteinsVisual AcuityLaser CoagulationAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth Factor

Citations

791

FWCI

69.20

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

References

Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials